Gut Microbiome

Microbiota therapeutics have transitioned from investigational FMT into FDA-approved live biotherapeutic products: Rebyota (RBL-2660) and Vowst (SER-109) for prevention of recurrent C. difficile infection. The track examines real-world durability, cost-effectiveness vs. fidaxomicin and bezlotoxumab, and emerging applications in IBD, hepatic encephalopathy, and ICI-refractory melanoma. Mechanistic sessions cover bile-acid signaling, short-chain fatty acid production, and engineered consortia. Diagnostic content addresses shotgun metagenomics standardization, the limits of 16S rRNA profiling, and the regulatory pathway for next-generation probiotics under FDA biologic frameworks.